|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.07M
2: EX-10.7 Material Contract HTML 34K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
13: R1 Document and Entity Information HTML 75K
14: R2 Consolidated Balance Sheets HTML 98K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 34K
16: R4 Consolidated Statements of Net Income/(Loss) and HTML 82K
Comprehensive Income/(Loss)
17: R5 Consolidated Statements of Changes in HTML 64K
Stockholders' Equity
18: R6 Consolidated Statements of Cash Flows HTML 90K
19: R7 Organization and Description of Business HTML 24K
20: R8 Basis of Presentation HTML 29K
21: R9 Summary of Significant Accounting Policies HTML 78K
22: R10 Product Revenue HTML 28K
23: R11 Net Loss Per Share HTML 45K
24: R12 Inventory HTML 38K
25: R13 Accrued Liabilities HTML 41K
26: R14 License Agreements and Commitments HTML 123K
27: R15 Stockholders' Equity HTML 29K
28: R16 Share-Based Compensation HTML 85K
29: R17 Related Party Transactions HTML 25K
30: R18 Income Taxes HTML 27K
31: R19 Other Benefits HTML 24K
32: R20 Gain From Sale of Priority Review Voucher HTML 24K
33: R21 Summary of Significant Accounting Policies HTML 100K
(Policies)
34: R22 Summary of Significant Accounting Policies HTML 59K
(Tables)
35: R23 Net Loss Per Share (Tables) HTML 43K
36: R24 Inventory (Tables) HTML 39K
37: R25 Accrued Liabilities (Tables) HTML 40K
38: R26 License Agreements and Commitments (Tables) HTML 115K
39: R27 Share-Based Compensation (Tables) HTML 79K
40: R28 BASIS OF PRESENTATION - Accumulated deficit and HTML 27K
cash (Details)
41: R29 BASIS OF PRESENTATION - Secondary public offering HTML 34K
(Details)
42: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Operating Leases (Details)
43: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K
Concentration of Credit Risk (Details)
44: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Inventory (Details)
45: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 40K
Value Measurement (Details)
46: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 41K
Revenue Recognition - License Revenue (Details)
47: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Segment (Details)
48: R36 Product Revenue (Details) HTML 44K
49: R37 NET LOSS PER SHARE - Basic and diluted (Details) HTML 46K
50: R38 NET LOSS PER SHARE - Anti-dilutive securities HTML 23K
(Details)
51: R39 Inventory (Details) HTML 28K
52: R40 Accrued Liabilities (Details) HTML 36K
53: R41 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 57K
MabVax License Agreement (Details)
54: R42 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 39K
agreements (Details)
55: R43 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 59K
agreements (Details)
56: R44 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 30K
(Details)
57: R45 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 38K
maturities (Details)
58: R46 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 26K
and discount rate (Details)
59: R47 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 40K
Preferred Stock (Details)
60: R48 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 66K
non-employees (Details)
61: R49 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 36K
(Details)
62: R50 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 32K
63: R51 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 41K
64: R52 SHARE-BASED COMPENSATION - Stock option expense HTML 33K
(Details)
65: R53 SHARE-BASED COMPENSATION - Stock option activity HTML 60K
(Details)
66: R54 SHARE-BASED COMPENSATION - Stock option HTML 28K
unrecognized compensation (Details)
67: R55 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 56K
Activity (Details)
68: R56 Related Party Transactions (Details) HTML 34K
69: R57 INCOME TAXES - Expense (Details) HTML 34K
70: R58 INCOME TAXES - Uncertain tax positions (Details) HTML 23K
71: R59 Other Benefits (Details) HTML 28K
72: R60 Gain From Sale of Priority Review Voucher HTML 34K
(Details)
74: XML IDEA XML File -- Filing Summary XML 133K
12: XML XBRL Instance -- ymab-20210331x10q_htm XML 1.24M
73: EXCEL IDEA Workbook of Financial Reports XLSX 80K
8: EX-101.CAL XBRL Calculations -- ymab-20210331_cal XML 115K
9: EX-101.DEF XBRL Definitions -- ymab-20210331_def XML 452K
10: EX-101.LAB XBRL Labels -- ymab-20210331_lab XML 1.07M
11: EX-101.PRE XBRL Presentations -- ymab-20210331_pre XML 804K
7: EX-101.SCH XBRL Schema -- ymab-20210331 XSD 146K
75: JSON XBRL Instance as JSON Data -- MetaLinks 316± 463K
76: ZIP XBRL Zipped Folder -- 0001558370-21-006293-xbrl Zip 277K
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Exhibit 10.7
AMENDMENT NO. 1
to
LICENSE AGREEMENT
for MSK’S technology
“[***] and [***] antibodies and Multimerization
Technology” between
MEMORIAL SLOAN-KETTERING CANCER CENTER
and
Y-MABS THERAPEUTICS, INC.
DATED: MARCH 18, 2021
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
AMENDMENT NO. 1 TO LICENSE AGREEMENT
This Amendment No. 1 dated February , 2021 (the “Amendment”), is made to that certain License Agreement for MSK’s technology “[***] and [***] antibodies and Multimerization Technology” dated August 20, 2015 (the “License Agreement”), by and between Memorial Sloan Kettering Cancer Center (“MSK”), a New York not-for-profit corporation, with its principal offices at 1275 York Avenue, New York, NY 10065; and Y-mAbs Therapeutics, Inc., a Delaware corporation, with its principal offices located at 230 Park Avenue, Suite 3350, New York, NY 10169 (“LICENSEE”). MSK and LICENSEE are sometimes referred to herein singly as a “Party” and collectively as “Parties”.
All capitalized terms not otherwise defined herein shall have the meanings assigned to them in the License Agreement.
W I T N E S S E T H
WHEREAS, Parties wish to amend and clarify certain aspects of the License Agreement only in the respects and on the conditions hereinafter stated.
NOW THEREFORE, in consideration of the mutual premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
ARTICLE 1- AMENDMENT
1.1 Under Section 1.21, “Customary distribution of samples of Licensed Product or related performance of Licensed Services by LICENSEE or Affiliates shall not be included in any calculation of Net Sales” is h ereby deleted in its entirety and replaced with the following:
“Distribution without charge of Licensed Products by LICENSEE, Sublicensee or Affiliates or related performance without charge of Licensed Services:
| (i) | in connection with patient assistance programs; |
| (ii) | for customary distribution of samples; |
| (iii) | for charitable donation purposes, early access programs, compassionate use or other similar programs; |
| (iv) | for preclinical, clinical, or registration studies; or |
| (v) | for use in any tests or studies reasonably necessary to comply with any applicable law, regulation or request by a Regulatory Authority or other governmental purposes; |
shall in, each case, not be included in any calculation of Net Sales.”
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
ARTICLE 2– MISCELLANEOUS
2.1 The Parties agree that, apart from the parts specifically amended hereunder, all terms and conditions of the License Agreement remain and shall remain in full force and effect.
[Signature page follows]
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
IN WITNESS WHEREOF, each of the Parties hereto has caused this Amendment to be executed by its duly authorized representative, all as of the day and year first written above.
| | |
| MEMORIAL SLOAN KETTERING CANCER CENTER | |
| | |
| By: | /s/ Eric Cottington |
| Name: | |
| Title: | Senior Vice President, Research and Technology Management |
| | |
| Y-MABS THERAPEUTICS, INC. | |
| By: | /s/ Thomas Gad |
| Name: | |
| Title: | Founder, Chairman and President |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/6/21 | 8-K | ||
| For Period end: | 3/31/21 | |||
| 3/18/21 | ||||
| 8/20/15 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA 3/01/22 Y-mAbs Therapeutics, Inc. 10-K 12/31/21 93:10M Toppan Merrill Bridge/FA 11/04/21 Y-mAbs Therapeutics, Inc. 10-Q 9/30/21 76:7.4M Toppan Merrill Bridge/FA 8/09/21 Y-mAbs Therapeutics, Inc. 10-Q 6/30/21 76:7.2M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |